原始出處紀錄
決策級主要結果 (Topline)
COMPASS Pathways 公布 COMP360 用於 TRD 的 COMP006 第三期試驗正面數據
COMP006 為第二項關鍵性第三期試驗，其主要終點達成高度統計顯著的 MADRS 改善（第 6 週，P<0.001），並在 26 週內持續分離。結合 COMP005，兩項試驗在超過 1,000 名 TRD 患者中提供一致且持久的療效數據，支持持續滾動式 NDA 提交，預計於 2026 年第四季完成。
關鍵事實
來源摘錄
EX-99.1 2 a8-kdated7july2026ex991.htm EX-99.1 a8-kdated7july2026ex991 © Compass Pathways | 1 Compass Pathways Phase 3 COMP006 data review July 7, 2026 © Compass Pathways | 2 Cautionary Note Regarding Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, you can identify forward-looking statements by terms such as “believe,” “continue,” “could,” “estimate，” “expect，” “may，” “might，” “plan，” “potential，” “project，” “target，” “will，” “would，” or the negative of these terms, and similar expressions intended to identify forward-looking statements. However, not all forward-looking statements contain these identifying words. These forward-looking statements includ